Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/185—Magnoliopsida (dicotyledons)
  • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
  • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
  • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/47—Quinolines; Isoquinolines
  • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
  • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/185—Magnoliopsida (dicotyledons)
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Definitions

• This patent application pertains to a food composition capable of suppressing the negative ef fects of the blood alcohol level , lowering the alcohol level in the blood by promoting its metabol ism .
• the found subj ect of thi s patent application is applicable in the field of producing food compositions , particularly liquid food compositions , speci fically in the sector of producing liquid food compositions as dietary supplements for use in preventing and treating the afteref fects of excessive alcohol consumption .
• ethanol is metaboli zed to acetaldehyde and from acetaldehyde to acetate through an enzyme - alcohol dehydrogenase (ALDH) - predominantly found in hepatic mitochondria .
• Acetate is released into the bloodstream from the liver and then trans ferred to tissues .
• ROS reactive oxygen species
• Vitamin E deficiency increases lipid peroxidation (LPO) , leading to increased production of malondialdehyde (MDA) [9] .
• Vitamin A deficiency contributes to lysosomal damage, while decreased glutathione content leads to mitochondrial dysfunction and increased susceptibility of cells to apoptosis State of the art
• the physiological time for reducing the alcohol level in the human body is dependent on the alcohol concentration itself. For instance, 12 grams of alcohol are metabolized within a variable timeframe, ranging between two to three hours, based on factors such as the individual's weight, gender, dietary conditions (full or empty stomach) , and liver condition.
• a first set of products consists of plant extracts containing polyphenols, purportedly aiming to increase the activity of antioxidant enzymes like superoxide dismutase and reduce c i r cul a L mg MJJA.
• preparations are known in the state of the art containing a mixture of silybin, silicristin, and silidianin in ratios of 3:1:1, known as Silymarin, supplemented with other components that appear to have an immediate detoxifying action, reducing the alcohol content in the blood in the short term.
• Creatine promotes ATP formation, helping to counteract the feeling of fatigue caused by alcohol intoxication.
• Silybum marianum extract works on the digestive function with a purifying and antioxidant action. Specifically, the silymarin— a complex of bioflavonoids within the extract- acts as a defense against various intoxicating substances, including alcohol.
• Patent US2019298684 describes a composition to reduce or mitigate the negative effects resulting from the consumption of alcoholic beverages.
• This composition includes dihydromyricetin C15H12O, a source of free-form silymarin, and pyrroloquinoi ine quinone.
• the free-form silymarin despite its known positive effects, appears to be inefficiently assimilated by the body, resulting in a loss of effectiveness of the composition.
• the purpose of the present patent application is to create a food composition for use in preventing and treating the aftereffects of intoxication, where said composition acts on the alcohol concentration in the blood.
• the further purpose of the invention described in this patent application is to create a discovery that can decrease the concentration of alcohol in the blood within a timeframe shorter than the physiologically necessary time, which, in an average individual, typically takes about 2-3 hours.
• Another purpose of the invention subject to this patent application is to create a dietary composition for the prevention and treatment of hangover symptoms, said composition aiming to have effects in reducing oxidative stress.
• the subject matter of this patent application is a food product comprising a complex of Silybum Marianum and phospholipids, hereinafter referred to as 'silymarin phytosome, ' sodium salt of pyrroloquinoline quinone, and 3, 5, 7-Trihydroxy-2 (3,4,5 — trihydroxyphenyl) -4-chromenone, hereinafter referred to as 'myricetin.
• This product is preferably, but not exclusively, in an aqueous solution.
• the invention subject to this patent application consists of a food preparation, referred to as such, comprising flavonoids and peptides in an aqueous solution.
• the food preparation subject to this patent application includes:
• Flavonoids silymarin phytosome, myricetin,
• Peptides sodium salt of pyrroloquinoline; said preparation being able to act on alcohol levels and oxidative stress markers caused by alcohol intake.
• the invention subject to this patent application consists of a liquid food preparation.
• the liquid composition of the product subject to this patent application consists of silymarin phytosome in a percentage ranging from 0.203 to 0.30%, sodium salt of pyrroloquinoline quinone in a percentage ranging from 0.03% to 0.10%, myricetin in a percentage ranging from 0.50% to 0.80%, H2O in a percentage ranging from 60% to 75%, and components commonly known in the relevant field for formulating liquid food products in a percentage ranging from 25% to 40%.
• the commonly known components in the relevant field for formulating liquid food products can include, by way of example and not limitation, fructose, citric acid, flavors, potassium sorbate, and sodium benzoate.
• the solid composition of the product subject to this patent application consists of silymarin phytosome in a percentage ranging from 10% to 15%, sodium salt of pyrroloquinoline quinone in a percentage ranging from 2% to 4%, myricetin in a percentage ranging from 30% to 40%, and components known for formulating solid food products in a percentage ranging from 41% to 58%.
• the known components for formulating solid food products can consist of N-Acetylcysteine, flavors, glyceryl monobehenate, silica, sucralose.
• CBC complete blood count
• AST ALT
• GGT total and fractionated bilirubin
• the alcoholic beverage administered consisted of a quantity of 150 ml of Cabernet red wine (alcohol content: 12.5-13%; alcohol content per serving: 14.81 - 15.40 g, corresponding to the average drink size as indicated by Kerr et al.) throughout the duration of the experiment and for ail subjects.
• the placebo or the product subject to this patent application was consumed immediately after drinking the glass of wine. Subjects then continued consumption for a week by drinking, in similar manners, one glass (150 ml; at lunch and one at dinner (total of 300 ml/day, approximately 30g of alcohol/day) of the provided red wine, while taking the prescribed placebo or the product subject to this patent application (according to the randomization group) .
• Table 1 shows that the blood alcohol concentration at day 1, 120 minutes after intake, is over 33% higher in those who took the placebo compared to those who took the product subis i s p a t e n t app 1 i cat
• the histogram in Table 2 displays the value of ethyl glucuronide (EtG) , a metabolic product of ethanol formed in the body through conjugation of ethanol with glucuronic acid, measured on day 1 at 120 minutes after intake.
• EtG ethyl glucuronide
• the redox state namely the analysis of amino thiols, was quantified from RBC (Red Blood Cells) using HPLC.
• the histogram shows an increasing trend in uric acid at 7 days (+35%) after intake of the product subject to this patent application. This data strengthens the statistical significance of Total Antioxidant Capacity (TAG) , supporting the concept of the antioxidant power of the product under this patent application. (Table 12B) .

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Natural Medicines & Medicinal Plants (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Mycology (AREA)
• Botany (AREA)
• Microbiology (AREA)
• Medical Informatics (AREA)
• Biotechnology (AREA)
• Alternative & Traditional Medicine (AREA)
• Nutrition Science (AREA)
• Food Science & Technology (AREA)
• Polymers & Plastics (AREA)
• Diabetes (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Hematology (AREA)
• Obesity (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=85381066

Family Applications (1)

Country Status (2)

Families Citing this family (1)

Family Cites Families (6)

• 2023
  • 2023-12-11 EP EP23841545.9A patent/EP4633390A1/de active Pending
  • 2023-12-11 WO PCT/IT2023/050275 patent/WO2024127440A1/en not_active Ceased

Also Published As

Similar Documents

Legal Events